@article {Shieh2023.01.30.23285099, author = {Joseph T Shieh and Jesus A Tintos-Hern{\'a}ndez and Chaya N. Murali and Monica Penon-Portmann and Marco Flores-Mendez and Adrian Santana and Joshua A. Bulos and Kang Du and Lucie Dupuis and Nadirah Damseh and Roberto Mendoza-Londo{\~n}o and Camilla Berera and Julieann C Lee and Joanna J Phillips and C{\'e}sar A P F Alves and Ivan J Dmochowski and Xilma R Ortiz-Gonz{\'a}lez}, title = {Heterozygous Nonsense Variants in the Ferritin Heavy Chain Gene FTH1 Cause a Novel Pediatric Neuroferritinopathy}, elocation-id = {2023.01.30.23285099}, year = {2023}, doi = {10.1101/2023.01.30.23285099}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Ferritin, the iron storage protein, is composed of light and heavy chain subunits, encoded by FTL and FTH1, respectively. Heterozygous variants in FTL cause hereditary neuroferritinopathy, a type of neurodegeneration with brain iron accumulation (NBIA). Variants in FTH1 have not been previously associated with neurologic disease. We describe the clinical, neuroimaging, and neuropathology findings of five unrelated pediatric patients with de novo heterozygous FTH1 variants. Children presented with developmental delay, epilepsy, and progressive neurologic decline. Nonsense FTH1 variants were identified using whole exome sequencing, with a recurrent de novo variant (p.F171*) identified in three unrelated individuals. Neuroimaging revealed diffuse volume loss, features of pontocerebellar hypoplasia and iron accumulation in the basal ganglia. Neuropathology demonstrated widespread ferritin inclusions in the brain. Patient-derived fibroblasts were assayed for ferritin expression, susceptibility to iron accumulation, and oxidative stress. Variant FTH1 mRNA transcripts escape nonsense-mediated decay (NMD), and fibroblasts show elevated ferritin protein levels, markers of oxidative stress, and increased susceptibility to iron accumulation. C-terminus variants in FTH1 truncate ferritin{\textquoteright}s E-helix, altering the four-fold symmetric pores of the heteropolymer and likely diminish iron-storage capacity. FTH1 pathogenic variants appear to act by a dominant, toxic gain-of-function mechanism. The data support the conclusion that truncating variants in the last exon of FTH1 cause a novel disorder in the spectrum of NBIA. Targeted knock-down of mutant FTH1 transcript with antisense oligonucleotides rescues cellular phenotypes and suggests a potential therapeutic strategy for this novel pediatric neurodegenerative disorder.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was made possible by philanthropic support via the NBIA Fund at the Childrens Hospital of Philadelphia. JTS thanks the Marcus Program in Precision Medicine and the Benioff Childrens Hospital, University of California San Francisco for their funding and support. IJD thanks the NSF, CHE-1905203. XOG thanks the Robert Wood Johnson Foundation (Harold Amos Faculty Development Program), NINDS (1K02NS112456-01A1) and the Burroughs Wellcome Fund (CAMS Award). Also, CHOP Roberts Collaborative for Genetics and Individualized Medicine (to XOG). We acknowledge the UCSF Brain Tumor SPORE Biorepository (NIH/NCI P50CA097257 JJP) for providing histology services.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of The Children{\textquoteright}s Hospital of Philadelphia gave ethical approval for this work. IRB of the University of California San Francisco gave ethical approval for this work. IRB of the Baylor College of Medicine gave ethical approval for this work. IRB of the Hospital for Sick Children gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.}, URL = {https://www.medrxiv.org/content/early/2023/01/31/2023.01.30.23285099}, eprint = {https://www.medrxiv.org/content/early/2023/01/31/2023.01.30.23285099.full.pdf}, journal = {medRxiv} }